CGMS sensor will be inserted 3 days prior to visit 2 and removed at visit 2 (day 1), and 3 days prior to Visit 5 (Week 24 ±4 weeks) and removed at Visit 5. 72-hr CGMS records before and after vildagliptin treatment will be collected.

Patients with history of hepatic impairment but not limited to those with pretreatment AST or ALT >2.5x ULN at Visit 1

Other protocol-defined inclusion/exclusion criteria may apply.

Contacts and Locations

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study.
To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.
For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01582243